17:27 · 2 April 2025

BREAKING: Novavax shares tumble as FDA misses deadline For Covid-19 vaccine approval

Novavax
Shares
NVAX.US, Novavax Inc
-
-

The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.

This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.

 

Source: xStation 

8 October 2025, 17:58

UBS raises Micron’s price target. Shares are rising!

8 October 2025, 15:19

US OPEN: Wall Street not afraid of Shutdown 📈💲

8 October 2025, 14:27

Phew, the rally is back on, as AI boom continues

8 October 2025, 07:05

Gold powers to fresh record, as stocks slip, but there could still be further upside to come

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.

Join over 1.7 Million investors from around the world